RNLXY · Renalytix plc · Analyst Estimates
$3.58
+0.03 (+0.70%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“As a result of the Company's losses and its projected cash needs, as defined in the accounting literature, substantial doubt exists about the Company's ability to continue as a going concern. While subsequent to September 30, 2024, the company has successfully raised approximately $14.9 million, net of expenses, in new equity capital and restructured the existing long-term debt recorded on the balance sheet, the Company does have a history of operating losses and it has been expensive to deliver all of the milestones to commercialize the kidneyintelX.dkd test. … As such, management has concluded that there is a going concern uncertainty. The consolidated financial statements do not include any adjustments that may result from the outcome of this going concern uncertainty.”View the 10-Q filed Nov 19, 2024
Market Cap
$47.43M
Shares
13.25M
Volume · Oct 20
3200
Avg daily vol (3M)
7239
Analyst Estimates
Compare analyst forecasts for Renalytix plc across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 10:01 UTC · Publication dates shown per estimate · 2 metric / period groups
FY ending 2025-06-30
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0.00
|
0.00
|
0.00
|
0
|
Q ending 2025-03-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0.00
|
0.00
|
0.00
|
0
|